



## Press Release

Aug 3, 2022

Eli Lilly Japan K.K.  
Sumitomo Pharma Co., Ltd.

### **Notice of conclusion of sales collaboration for GLP-1 receptor agonist “Trulicity® Subcutaneous Injection 0.75 mg Ateos®”**

Eli Lilly Japan K.K. (Head Office: Kobe, Japan, Representative Director and President: Simone Thomsen, hereinafter called “Eli Lilly Japan”) and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura, hereinafter called “Sumitomo Pharma”) announced that the domestic sales collaboration for Glucagon-like peptide-1 (GLP-1) receptor agonist “Trulicity® Subcutaneous Injection 0.75 mg Ateos®” (generic name: dulaglutide [recombinant], hereinafter called “Trulicity”), which is used for the treatment of type 2 diabetes, will conclude upon the expiration of the contract period on December 31, 2022.

Eli Lilly Japan and Sumitomo Pharma signed the domestic sales collaboration agreement for Trulicity in July 2015. Based on this agreement, Sumitomo Pharma has taken responsibility for sales/ distribution of Trulicity, while Eli Lilly Japan retains a manufacturing/ marketing license, and both companies have been providing information to medical professionals. With the expiration of the term of this agreement, from January 2023, Eli Lilly Japan will be responsible for sales/ distribution and will provide information. Sumitomo Pharma will end its sales/ distribution and information provision activities on December 31, 2022.

Eli Lilly Japan and Sumitomo Pharma will work closely together to facilitate transfer of Trulicity so as to ensure continued stable product supply and adequate information services.

**About Trulicity® Subcutaneous Injection 0.75 mg Ateos®**

Trulicity is a once-weekly GLP-1 receptor agonist that acts on the GLP-1 receptor in the way similar to that of the GLP-1, a gastrointestinal hormone. The product therefore facilitates insulin secretion when the blood sugar level increases after meal, depending on the blood sugar level in the body. Trulicity is provided as a disposable, pen-type auto-injector.

**About Eli Lilly Japan K.K.**

Eli Lilly Japan K.K. is a subsidiary of US-based Eli Lilly and Company. It contributes to medical treatment in Japan through the development, manufacture, import and sale of innovative pharmaceutical products that enable people to live longer, healthier, and more fulfilling lives, focusing on the therapeutic areas such as cancer, diabetes, musculoskeletal diseases, central nervous system diseases, autoimmune diseases, growth disorder, and pain. For more information, visit <http://www.lilly.co.jp>

**About Sumitomo Pharma Co., Ltd.**

Sumitomo Pharma Co., Ltd. defines its corporate mission as to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide. By channelling our efforts into the research and development of new drugs, Sumitomo Pharma aims to realize our mission and provide innovative and effective pharmaceutical solutions not only to people in Japan but also around the world. Sumitomo Pharma positions Psychiatry & Neurology area, Diabetes area, and Rare diseases area as Focus Areas for the Japan business. For more information, visit <https://www.sumitomo-pharma.com>

**<Contact Information>**

Yumi Yoshioka Corporate Affairs, Eli Lilly Japan K.K.  
TEL: +81-3-5574-9257 Email: [yoshioka\\_yumi@lilly.com](mailto:yoshioka_yumi@lilly.com)

Corporate Communications, Sumitomo Pharma Co., Ltd.  
(Osaka) TEL: +81-6-6203-1407 / (Tokyo) TEL: +81-3-5159-3300

<This press release has been distributed to the following press clubs: Heavy Industry Study, Honcho, Doshomachi Yakugyo, Osaka Chemical industry >